Tracking malaria resistance and immunity in Uganda
Program for Resistance, Immunology, Surveillance & Modeling of Malaria in Uganda (PRISM) Renewal
This program follows malaria infections, drug and insecticide resistance, and immune responses in Ugandan communities to help protect children and families.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11401046 on NIH RePORTER |
What this research studies
If you join, you or your child will visit participating clinics and may give small blood samples and answer health questions so researchers can follow infections, treatments, and immune responses over time. Laboratories will test parasite samples for drug‑resistance markers and measure antibodies that show past malaria exposure. Teams also monitor local mosquitoes and insecticide resistance and combine those findings with mathematical models to spot changing risks. The information is shared with health officials to help improve treatment choices and prevention where you live.
Who could benefit from this research
Good fit: Ideal participants are people living in malaria‑endemic parts of Uganda—especially young children and clinic patients—who can provide brief samples and attend follow‑up visits.
Not a fit: People who live outside Uganda, who are not exposed to malaria, or who cannot attend participating clinics or provide samples are unlikely to benefit directly.
Why it matters
Potential benefit: If successful, the program can detect emerging drug or insecticide resistance early and help guide treatments and prevention that reduce illness and deaths.
How similar studies have performed: Previous PRISM work and similar surveillance programs in Africa have successfully identified resistance patterns and informed changes in treatment and control strategies.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Dorsey, Matthew G — University of California, San Francisco
- Study coordinator: Dorsey, Matthew G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.